TickerLSTA
SectorBiotechnology
Mkt cap$29M
EV / EBITDAN/A
PostureHigh Velocity
Composite70/100
LensTarget-side

SE-Cluster Research·Issuer Brief·Q2 2026CIK 320017

Lisata Therapeutics, Inc.

LSTAHIGH VELOCITYFILING INTENSITY

Lisata Therapeutics, Inc. reads as High Velocity (composite 70/100); pressure / disclosure signals dominate the posture this cycle · primary market Healthcare.

Lens

Disclosed M&A capital (2023–2025)

N/A

−99%

vs N/A in 2020–2022

Disclosed transactions

N/A

−99%

0/3 active fiscal years in window

Buyer archetype

Consistent Strategic Buyer

Meaningful spend appears across repeat years.

Composite score

/100

High Velocity dominates · Filing Intensity

Financial snapshotRevenue$170K
EBITDAN/A
Enterprise value$13M
EV / Revenue74.9×
EV / EBITDAN/A
P/EN/A
Cash$16M
Total debtN/A
as of 2026-05-10

§ I·SE-Cluster Issuer Brief

Behavioral posture, nine reads.

Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.

Active Acquirer

15/100

Companies actively deploying disclosed capital into M&A

$72M disclosed buyer spend

Buyer Cadence

18/100

Buyer-side companies with recent filing activity

Filed within 36d
341 8-Ks

Target Probability

20/100

Issuers showing target-side patterns from filings

30 activism filings

Spin/Carve

0/100

Issuers showing spin-off, carve-out, or sum-of-parts posture

30 activism filings

Pressure Watch

15/100

Issuers facing activism, governance, or control pressure

30 activism filings
Latest activism 16y ago; heavily discounted

Distress Watch

44/100

Issuers showing financial-distress filing patterns

10-Q 215d stale
30 activism filings

Restatement Risk

2/100

Issuers with accounting-integrity flags from filings

6 auditor changes
19 NT late filings
Latest event 15y ago; heavily discounted

Capital Velocity

Dominant

70/100

Issuers with the highest filing-activity intensity

341 8-Ks
5 form types

Quiet Power

0/100

Large issuers with low signal volume and clean disclosure cadence

Enterprise value $13M
10-Q 215d ago
3 active signals

§ II·SE-Cluster Issuer Brief

Capital cadence.

Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.

Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $3M · Peak count: 1

FY	Disclosed buys	Disclosed spend	Avg ticket	Audited tier
2025	N/A	N/A	N/A	N/A
2024	N/A	N/A	N/A	N/A
2023	N/A	N/A	N/A	N/A
2022	1	$3M	$3M	N/A
2021	N/A	N/A	N/A	N/A
2020	N/A	N/A	N/A	N/A

§ III·SE-Cluster Issuer Brief

Strategy posture.

The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.

Archetype mix

Platform
20%
Technology Acquisition
20%
Geographic Expansion
20%
Vertical Integration
20%
Talent Acquisition
20%

Strategy keywords

Terms recurring across recent 10-K acquisition disclosures.

platform
technology_acquisition
geographic_expansion
vertical_integration
talent_acquisition

§ IV·SE-Cluster Issuer Brief

Filing language.

Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.

“With the acquisition of California Stem Cell in May 2014, NeoStem has undertaken the continued development of a patient-specific cancer immunotherapy now known as NBS20”

10-KFY2014

“NBS20, which uses a patient’s own immune cells and tumor or cancer initiating cells to create a therapeutic vaccine, is currently in Phase 3 clinical investigation”

10-KFY2014

“We expect to complete enrollment for this study in 2013 with the first data readout available six to eight months thereafter.”

10-KFY2012

“In January 2012, we enrolled the first patient in our PreSERVE Phase 2 trial, a multicenter, randomized, double-blind, placebo-controlled U.S. clinical trial to evaluate the efficacy and safety of a single intra-coronary infusion of at least 10 million cells of AMR-001, post STEMI, in subjects with ejection fractions of 48% or less as measured by cardiac magnetic resonance imaging ("CMR").”

10-KFY2012

“we acquired the rights to data and regulatory filings for a CD34+ cell therapy program”

10-KFY2018

§ V·SE-Cluster Issuer Brief

Market context.

Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.

Primary market

Healthcare

Market spend (2023–2025): $195B
Market spend (2020–2022): $253.6B
Recent vs prior: −23%
Issuer rank in market: N/A
Share of market capital: 0.0%

Valuation positioning

N/AEV / EBITDA

LSTA trades at a -13.7-turn discount to the Healthcare peer median of 12.9×.

EV / Revenue: 74.9×
Net debt / EBITDA: N/A
Peer median EV / EBITDA: 12.9×

Trading comparables

FMP market data · 2026-05-10

Company	EV / EBITDA	EV / Rev	Net debt / EBITDA	Revenue	M&A 2023–2025
AbbVie Inc.ABBV	23.4×	6.7×	3.1×	$62.8B	$18B
UnitedHealth Group IncorporatedUNH	17.2×	0.9×	1.9×	$449.7B	$28.1B
Amgen Inc.AMGN	12.9×	6.0×	2.6×	$37.2B	$26.7B
Elevance Health, Inc.ELV	11.7×	0.5×	2.5×	$200.4B	$6.4B
HCA Healthcare, Inc.HCA	9.3×	1.9×	2.8×	$76.4B	$1.3B

Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.

§ VI·SE-Cluster Issuer Brief

Buyer landscape.

Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.

Likely buyers

No public buyers surface as a strong target-side fit on current signal.

Likely sellers / divestiture partners

No reciprocal divestiture / strategic-alternatives matches identified.

§ VII·SE-Cluster Issuer Brief

Filing activity & signal stream.

Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.

Filing cadence

10-K (annual)442026-04-28
10-Q (quarterly)962025-11-06
8-K (event)3412026-05-04
Proxy / DEF 14A492025-04-25
Activism (13D / DFAN / PREC)302010-05-20

Signals on file

elevated
Auditor change
2011-08-24
6 Item 4.01 filings on file; certifying accountant change.
watch
Late-filing notice
2011-05-17
19 NT 10-K/10-Q filings on file.
elevated
Activism on file
2010-05-20
30 activist filings on file (13D, DFAN14A, PREC14A series).
info
Signal
Serial acquisition history
info
Signal
10-K strategy themes
info
Signal
Restatement risk

§ VIII·SE-Cluster Issuer Brief

Audited corpus.

No audited record on file for this CIK in the current v6 corpus.

This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.

Search